In notes on an informal meeting with the DHSS, Clive Collins noted that the HTLV-3 viral inactivation studies needed to be repeated.
Linked evidence
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Viral Inactivation